{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:11:15Z","timestamp":1789499475664,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104985","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:53:29Z","timestamp":1761184409000},"page":"104985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Chromophobe renal cell carcinoma: Emerging vulnerabilities as a promise for a new therapeutic landscape"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6025","authenticated-orcid":false,"given":"Samer","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Alchoueiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Henske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2025.104985_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104985_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102359","article-title":"Targeting KIT with Antibody-Drug conjugates in chromophobe renal cell carcinoma","volume":"23","author":"Alchoueiry","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104985_bib4","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.onc.1210796","article-title":"The cystine\/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death","volume":"27","author":"Banjac","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-210010","article-title":"\"PROBE\"ing the role of cytoreductive nephrectomy in advanced renal cancer","volume":"6","author":"Bell","year":"2022","journal-title":"Kidney Cancer J."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104985_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"7784","key":"10.1016\/j.critrevonc.2025.104985_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib8","first-page":"47","article-title":"Structure, function, and regulation of human cystine\/glutamate transporter in retinal pigment epithelial cells","volume":"42","author":"Bridges","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104985_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clgc.2019.06.011","article-title":"Chromophobe renal cell carcinoma: results from a large Single-Institution series","volume":"17","author":"Casuscelli","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41419-022-04501-9","article-title":"Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104985_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104985_bib12","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"7784","key":"10.1016\/j.critrevonc.2025.104985_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104985_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103287","article-title":"Comprehensive review of chromophobe renal cell carcinoma","volume":"160","author":"Garje","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104985_bib15","doi-asserted-by":"crossref","first-page":"TPS4604","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4604","article-title":"NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)","volume":"41","author":"Hall","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104985_bib16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","article-title":"Chromophobe renal cell carcinoma","volume":"41","author":"Henske","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104985_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2021.03.015","article-title":"A Single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma","author":"Hutson","year":"2021","journal-title":"Eur. Urol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104985_bib18","doi-asserted-by":"crossref","first-page":"12387","DOI":"10.1016\/S0021-9258(18)43284-X","article-title":"Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine","volume":"256","author":"Ishii","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104985_bib19","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2023.41.16_suppl.4597","article-title":"CABOSUN II: results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. Sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC)","volume":"41","author":"Johns","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104985_bib20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41590-022-01213-2","article-title":"Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies","volume":"23","author":"Kansler","year":"2022","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104985_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176743","article-title":"Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma","volume":"9","author":"Kapur","year":"2024","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104985_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.1711670303","article-title":"Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas","volume":"167","author":"Kovacs","year":"1992","journal-title":"J. Pathol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104985_bib23","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC database consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104985_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00234","article-title":"Tumor-Intrinsic and microenvironmental determinants of impaired antitumor immunity in chromophobe renal cell carcinoma","author":"Labaki","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104985_bib25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104985_bib26","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104985_bib27","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2023.41.16_suppl.4520","article-title":"Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh)","volume":"41","author":"McGregor","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104985_bib29","doi-asserted-by":"crossref","first-page":"TPS4593","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4593","article-title":"A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL\/Alliance A031801)","volume":"39","author":"McKay","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104985_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev.bi.52.070183.003431","article-title":"Glutathione","volume":"52","author":"Meister","year":"1983","journal-title":"Annu Rev. Biochem."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104985_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world health organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104985_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104985_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101492","article-title":"Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype","volume":"11","author":"Ohashi","year":"2019","journal-title":"Cancers"},{"issue":"33","key":"10.1016\/j.critrevonc.2025.104985_bib34","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: Results from the COSMIC-021 study","volume":"39","author":"Pal","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12904-024-01548-7","article-title":"A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol","volume":"23","author":"Palma","year":"2024","journal-title":"BMC Palliat. Care"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib36","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1038\/s41467-021-27414-1","article-title":"Molecular basis for redox control by the human cystine\/glutamate antiporter system xc","volume":"12","author":"Parker","year":"2021","journal-title":"Nat. Commun."},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104985_bib37","doi-asserted-by":"crossref","first-page":"E6274","DOI":"10.1073\/pnas.1710849115","article-title":"Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma","volume":"115","author":"Priolo","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104985_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18632\/oncoscience.130","article-title":"Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies","volume":"2","author":"Rathmell","year":"2015","journal-title":"Oncoscience"},{"issue":"357","key":"10.1016\/j.critrevonc.2025.104985_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104985_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-025-03562-2","article-title":"Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma","author":"Salem","year":"2025","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104985_bib41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.euf.2018.01.016","article-title":"Metabolic and lipidomic reprogramming in renal cell carcinoma subtypes reflects regions of tumor origin","volume":"5","author":"Schaeffeler","year":"2019","journal-title":"Eur. Urol. Focus"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104985_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2020.03.003","article-title":"Next-generation RNA Sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms","volume":"78","author":"Skala","year":"2020","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104985_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02890129","article-title":"Human chromophobe cell renal carcinoma","volume":"48","author":"Thoenes","year":"1985","journal-title":"Virchows Arch. B Cell Pathol. Incl. Mol. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104985_bib44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdt578","article-title":"Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies","volume":"25","author":"Voss","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104985_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-20-0754","article-title":"Decreased mitochondrial DNA content drives OXPHOS dysregulation in chromophobe renal cell carcinoma","author":"Xiao","year":"2020","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104985_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104105","article-title":"Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes","volume":"10","author":"Xu","year":"2025","journal-title":"ESMO Open"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104985_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104985_bib48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41588-020-0629-y","article-title":"Author correction: comprehensive molecular characterization of mitochondrial genomes in human cancers","volume":"55","author":"Yuan","year":"2023","journal-title":"Nat. Genet."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104985_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153652","article-title":"Immune checkpoint inhibition in advanced non-clear cell renal cell carcinoma: leveraging success from clear cell histology into new opportunities","volume":"13","author":"Zarrabi","year":"2021","journal-title":"Cancers"},{"issue":"6_","key":"10.1016\/j.critrevonc.2025.104985_bib50","doi-asserted-by":"crossref","first-page":"TPS366","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS366","article-title":"PDIGREE: an adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)","volume":"39","author":"Zhang","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2025.104985_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122840119","article-title":"Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104985_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103240118","article-title":"Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:15:46Z","timestamp":1767388546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"alternative-id":["S1040842825003737"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104985","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chromophobe renal cell carcinoma: Emerging vulnerabilities as a promise for a new therapeutic landscape","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104985"}}